Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...
(PDCs) demonstrate tumor-selective delivery and potent anticancer activityPreclinical data show robust efficacy ...
IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study ...
CBX-12 is a first-in-class PDC that utilizes Cybrexa’s proprietary alphalex technology to enhance the intracellular delivery of exatecan, a highly potent, well-established TOP1 inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback